Deluxe to Report Second Quarter 2025 Results on August 6, 2025
About Deluxe
Deluxe, a Trusted Payments and Data company, champions business so communities thrive. Our solutions help businesses pay, get paid, and grow. For more than 100 years, Deluxe customers have relied on our solutions and platforms at all stages of their lifecycle, from start-up to maturity. Our powerful scale supports millions of small businesses, thousands of vital financial institutions and hundreds of the world's largest consumer brands, while processing more than $2 trillion in annual payment volume. Our reach, scale and distribution channels position Deluxe to be our customers' most trusted business partner. To learn how we can help your business, visit us at www.deluxe.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Why Lemonade Stock Dropped 14% in July, and Why It's Already Rebounding
Key Points Lemonade stock was sagging last month as home sales are still disappointing, and home insurance is its core product. Despite that, Lemonade reported outstanding second-quarter results. Lemonade stock could still be a bargain. 10 stocks we like better than Lemonade › Shares of insurance technology company Lemonade (NYSE: LMND) dropped 14% in July, according to data provided by S&P Global Market Intelligence. There wasn't any significant news directly related to the company, but the descent started after home sales data were released on July 23, and home insurance is a big part of Lemonade's business today. However, it dispelled those worries with a fantastic second-quarter report. The housing market is still sour Lemonade is a digital insurance company that sells insurance online, mostly through chatbots. It uses artificial intelligence (AI) and machine learning throughout its business, and its algorithms determine everything from policy pricing to regional marketing spend. It's only a decade old, but it's already made a strong mark on the industry, expanding its platform to cover most kinds of insurance and reaching most of the U.S. population. It's growing rapidly as customers enjoy the concept of being able to file a claim online and have it approved within minutes instead of needing to wait on hold for an insurance agent to answer their calls. Lemonade's original product was renters insurance, and renters and homeowners insurance are still the company's main products, accounting for about half of total in-force premium (IFP). Home sales data released in July from the National Association of Realtors showed that home sales hit a record high of $435,300 in June, up 2% from the year before, and pending home sales fell 0.8% from May. Experts were expecting 0.2%. People are holding off on buying homes, and the market was concerned about Lemonade's growth prospects. Sweetening the deal Lemonade released second-quarter earnings on Tuesday morning, and they were phenomenal, beating expectations across the board. IFP increased 29% year over year to over $1 billion, and total customer count increased 24% to nearly 2.7 million. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) loss and net loss both contracted year over year, and the trailing-12-month loss ratio improved by 3 percentage points sequentially. Home-related loss ratio, a metric associated with its oldest product, fell to 60%, demonstrating that its algorithms produce better results over time. Management raised guidance for the year, and it reiterated that it expects to be profitable on an adjusted EBITDA basis before the end of 2026. Lemonade stock soared on the news, and it's up 31% in one day as of this writing. It's likely to stabilize over the next few days, but it looks like it's finally becoming clear to the market that Lemonade is the future of insurance, and at the current price, it still looks like a bargain. Do the experts think Lemonade is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Lemonade make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,039% vs. just 181% for the S&P — that is beating the market by 858.19%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $631,505!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,103,313!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Jennifer Saibil has positions in Lemonade. The Motley Fool has positions in and recommends Lemonade. The Motley Fool has a disclosure policy. Why Lemonade Stock Dropped 14% in July, and Why It's Already Rebounding was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline
Animal health firm Zoetis Inc. (NYSE:ZTS) on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61. The company reported sales of $2.50 billion, up 4% year over year, beating the consensus of $2.41 billion. On an organic operational basis, revenue for the second quarter of 2025 increased 8% compared with the second quarter of 2024. Revenue in the U.S. segment was $1.4 billion, up 4% and 7% on an organic operational of the company's companion animal products increased 9%, driven primarily by Simparica Trio, the company's flea, tick, and heartworm combination product, as well as its key dermatology portfolio, including Apoquel, Apoquel Chewable, and Cytopoint. Broad-based growth across the remainder of the companion animal portfolio, including vaccines and diagnostics, was partially offset by a decline in the company's monoclonal antibody (mAb) products for osteoarthritis (OA) pain, Librela for dogs, and Solensia for cats. Sales of livestock products declined 21% in the quarter, largely due to the divestiture of the medicated feed additive product portfolio and related assets. On an organic operational basis, sales of livestock products decreased 2% in the quarter due to the timing of supply of ceftiofur products and competition for Draxxin, partially offset by growth across the livestock portfolio, primarily in vaccines. Guidance Zoetis raised its fiscal 2025 revenues guidance from $9.425 billion–$9.575 billion to $9.45 billion-$9.6 billion, compared to the consensus of $9.49 billion. View more earnings on ZTS The animal health company also raised the 2025 adjusted earnings per share from $6.20-$6.30 to $6.30-$6.40, compared to the consensus of $6.23. The company expects adjusted net income of $2.825 billion-$2.875 billion compared to the prior guidance of $2.775 billion-$2.825 billion. The company says the guidance reflects foreign exchange rates and the impact of enacted tariffs. With an eye on future growth, William Blair noted that sentiment around Librela, a key product in Zoetis's portfolio, remains subdued. However, they argue that the product's decline in the U.S. market may not significantly impact overall performance, particularly given the robust performance in the U.S. companion animal segment, which saw strong growth. The momentum in this area appears sufficient to offset the challenges posed by Librela's underperformance. Brandon Vazquez, an analyst at William Blair, commented, 'Investors have been questioning how Zoetis can sustain growth within its long-range plan amid rising competition and struggles with Librela. We think second-quarter results and raised full-year guidance should give incremental confidence that this is not the case.' Zoetis saw its shares initially rise following the release of its stronger-than-expected second-quarter results, alongside an upward revision of its fiscal 2025 EPS and revenue guidance. However, despite the positive report and raised outlook, Zoetis stock has since retraced its earlier gains. Price Action: ZTS stock is trading lower by 2.62% to $147.84 at last check Tuesday. Read Next:Photo by JHVEPhoto via Shutterstock Latest Ratings for ZTS Date Firm Action From To Mar 2022 Citigroup Maintains Neutral Dec 2021 Citigroup Maintains Neutral Nov 2021 Morgan Stanley Initiates Coverage On Overweight View More Analyst Ratings for ZTS View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? ZOETIS (ZTS): Free Stock Analysis Report This article Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNET
11 minutes ago
- CNET
Boost Your Productivity With This One-Day $400 Samsung 4K Monitor Deal
Adding a second monitor to your work station can seriously boost your productivity. So if you're looking to upgrade your home office, we've got a deal you won't want to miss. For today only, you can pick up this stunning 37-inch Samsung ViewFinity S8 monitor for $400 at Best Buy, which saves you $200 compared to the usual price. However, this offer is only available until 9:59 p.m. PT (12:59 a.m. ET) tonight, and could even sell out before then. Be sure to get your order in soon if you don't want to miss out on these savings. This Samsung monitor boasts some impressive specs that make it a great upgrade for most people. It features a dazzling 37-inch 4K UHD display which has HDR10 support for sharp details and true-to-life colors, making it an excellent option for creative professionals. Plus, it's easy to connect other monitors or peripherals thanks to the display port, HDMI port and multiple USB-C and USB-A ports. It is also TUV-certified for intelligent eye care, and has multiple safeguards to help reduce eye strain. The ergonomic stand allows you to adjust the height, tilt and swivel to help reduce the strain on your neck as well. Just note that with a 60Hz refresh rate and 5ms response time, it's not designed for fast-paced gaming. Why this deal matters With hardware that's focused on productivity rather than gaming, this Samsung monitor deal is a great option for those looking to upgrade their home office and don't want to spend unnecessary cash on specs that they don't need. It has a 37-inch 4K display, multiple display inputs and an adjustable stand that helps reduce the strain on your neck during long days. Plus, this deal is only available for today, so don't miss out.
